EN | TR
E-ISSN: 3061-9947
Fractioned Stereotactic Radiosurgery in Patients with Paraganglioma
PDF
Cite
Share
Request
Original Article
VOLUME: 50 ISSUE: 1
P: 30-35
2017

Fractioned Stereotactic Radiosurgery in Patients with Paraganglioma

Acta Haematol Oncol Turc 2017;50(1):30-35
DOI: 10.5505/aot.2017.29292
Ayşen Dizman
Ebru Atasever Akkaş
Gökçe Kaan Olcay
Emine Keven
1. Department of Radiation Oncology, Ankara Dr. Abdurrahman Yurtarslan Oncology Training and Research Hospital, Ankara, Turkey
2.
No information available.
No information available
Received Date: 2016-06-02T23:08:26
Accepted Date: 2017-04-05T15:07:33
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Paraganglioma are rare, indolent and highly vascular tumors. The treatment options for paraganglioma include surgery, conventional external beam radiotherapy (EBRT), stereotactic radio-surgery (SRS) or combination of these modalities. EBRT has been used to treat unresectable tumors and patients with residual or recurrent lesions after surgery The aim of this study is evaluated the results of treatment in patients with paraganglioma who were treated with fractioned stereotactic radiotherapy

METHODS

Nine patients with paraganglioma, who were treated with fractioned stereotactic radiotherapy, were retrospectively evaluated.Two patient was male, and others were female. The median dose to the tumor was 25 Gy in median 5 fractions

RESULTS

Median follow-up was 65 months (range, 46-71 months). All patients were evaluated with magnetic rezonance imaging, every 6 months. Lesions were stable in 3 patients, and it was observed complete response in 1 patient and partial response in 5 patients. We did not observe any treatment related acute toxicity in our patients. We observed late toxicity in 2 patients.

DISCUSSION AND CONCLUSION

In conclusion, according to our experience, fractioned stereotactic radiotherapy with CyberKnife® (AccurayIncorporated, Sunnyvale, CA) seems to be successful treatment option in the management of paraganglioma.